CONQUEST
4.4.2024 12:19:30 CEST | Business Wire | Press release
Conquest enters the Finnish renewable power market with the acquisition from BHM Renewables (a BHM group company) of a 182MW onshore wind portfolio developed by Winda Energy and the implementation of a broader strategic partnership towards further extensions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240404783244/en/
Shutterstock, Wind Portfolio in Finland
Conquest, a fund manager focusing on the infrastructures of the energy transition in Europe, through its fund Conquest Infrastructure SLP – Sustainable 2, has completed the concomitant acquisitions of two wind farms developed by Winda Energy, the Finnish renewable energy developer majority-owned by Czech BHM Renewables, part of the investment firm BHM group. The two onshore wind projects have a combined capacity of 182MW. Furthermore, the cooperation encompasses additional onshore wind projects totalling 500MW.
The transaction allows Conquest to expand its renewable power platform and its footprint in the Nordics market, while maintaining a well-balanced and diversified approach towards investments targeted to the energy transition in Europe. The transaction represents an expected phased total investment of approximately 1 billion euros, to be gradually deployed between 2024 and 2028, offering a fully green investment in one of Europe’s most stable and robust economies.
The first two wind projects are at an advanced stage of development, with the first 182MW expected to reach ready-to-build by Q4 2024 and the rest expected to reach the same stage by Q4 2025. Winda Energy Oy will complete the development and manage the construction with expected start dates of commercial operations ranging from 2026 to 2028 for the portfolio.
Frederic Palanque, Founder and Managing Director of Conquest said: “Conquest is thrilled to enter, in partnership with Winda Energy, in sustainable real assets in a market recognized for its robust renewable energy fundamentals and its ambitious net zero roadmap.”
“We are happy to cooperate with Conquest, a dynamic and reliable partner on our growth journey. The transaction secures the completion of some of our flagship projects over the next years, enabling us to extend our contribution to Finland’s green energy transition.”, says Tuomas Hooli, CEO of Winda Energy.
Michal Prause, Associate Partner at BHM Renewables, said: “We are extremely pleased with the outcome of the transaction, reflecting the deep development skills, which our affiliate Winda has been demonstrating on the Finnish renewable power market over the years. We are looking forward to the strategic partnership with the highly professional asset management and investment teams of Conquest.”
ABOUT
Conquest
Established in 2012, Conquest is an alternative asset management firm invested in sustainable and long-term value stemming from European infrastructures. Conquest invests in and operates long-life, high- quality assets and businesses on behalf of its clients, which range from large institutional investors to single-family offices. With a team of 20 collaborators, based in Dublin and Paris, the firm manages assets worth circa 500 million euros and 25 investments across Europe.
BHM group
BHM group is a rapidly expending European investment firm that manages dozens of European companies in Europe. In the energy sector, BHM group is focused on investments in renewable energy sources, with an emphasis on wind and solar energy, and is active in six countries in Central Europe and Scandinavia. Due to its extensive experience and many successful projects, BHM group companies can provide comprehensive services, encompassing development, construction, and operation. BHM group focuses on long-term and stable partnerships that take into account healthy economic growth and are in line with internationally recognized standards of social responsibility and sustainability.
Winda Energy
Winda Energy Oy is a leading Finnish renewable energy project developer with its current development portfolio consisting of 3 GW of onshore wind and 1 GW of solar PV across Finland. Winda Energy has extensive experience in the renewable sector and takes projects from their initial design to the end of construction, most recently completing the construction of 200 MW of onshore wind in 2023. Winda Energy is majority owned by BHM group.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240404783244/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ARIS Announced as Exclusive Process Intelligence Launch Partner for AWS European Sovereign Cloud8.6.2026 09:00:00 CEST | Press release
Partnership Will Enable Enterprises to Accelerate AI Adoption While Ensuring Digital Sovereignty ARIS, the process context foundation for enterprise AI deployment, today announced its collaboration with Amazon Web Services (AWS) to support organizations navigating increasingly complex digital sovereignty requirements while accelerating AI-driven transformation. Many European enterprises face growing pressure to ensure sensitive operational and business data remains under European governance and regulatory control. Through the AWS European Sovereign Cloud (ESC), they will be able to combine advanced cloud and AI capabilities with enhanced operational separation, EU-based governance, and strict data residency controls. ARIS will support customers looking to operationalize AI safely and at scale within these boundaries by providing the process intelligence, governance, and operational context required for trusted enterprise AI deployment. “AI is moving rapidly from experimentation to oper
Cosylab Launches PlanOne™ Treatment Planning System for Particle Therapy8.6.2026 08:00:00 CEST | Press release
Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workflow into a single environment. PlanOne™ is FDA 510(k) cleared. "PlanOne™ began with listening. Over the years, our work on control systems in radiation oncology has put us in direct, ongoing contact with medical physicists and clinical teams at some of the leading facilities in the world," said Mark Pleško, CEO of Cosylab. "Our partners have been clear on what matters most for particle therapy: physics accuracy they can defend, clinical confidence at the point of plan approval, and a platform built to grow with AI and adaptive workflows. We designed PlanOne™ around those three priorities, and we'll keep developing it together with the clinical community that helped shape it." Physics-accurate, radiobiologically informed planning PlanOne™ is built on a GPU-accelerated Monte Carlo dose engin
BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region8.6.2026 06:00:00 CEST | Press release
BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA’s established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA’s Broker-Dealer license from Dubai’s Virtual Assets Regulatory Authority (VARA). The launch further expands BitGo MENA’s regulated product suite under VARA’s oversight, marking another step in the region’s continued buildout of institutional digital asset infrastructure amid growing demand for integrated execution and custody solutions. “The Middle East and North Africa has quickly become one of the most exciting regions in the world for digital assets, with regulators, institutions, and innovators moving with real purpose,” said Mike Bels
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom